Message Font: Serif | Sans-Serif
 
No. of Recommendations: 3
I do not relative valuation is of much use here. Not any company in the pharma space has that kind of debt. And for the heck of it,

GILD is at 5.6x EBITDA. and 7-8x FCF. here are some simple numbers on GILD
There is NON - GAAP BULL bull $$$$

Market Cap $120B
$4B net cash
FCF $20B


That is 6x FCF. Forget 10x Debt to FCF. This Is 6x P/FCF.

But just because it is so cheap, does not make it a buy. There are fears about peak revenues for its HEP C drug and competition. None of that is even in the numbers yet...

And check its history in terms of numbers, drugs discovery , approval etc. HIV leader and Hep C and then a backlog too.

So why would you buy any thing with that kind of debt and non- trusted revenues etc etc...

When you can buy a Pure GAAP / FCF machine for 6-7x FCF. (trailing)..

I think people love catching falling knives. and the fact that it fell from $250 makes people think the upside is multi fold. No one thinks hey maybe that $200+ level was just baloney.... that only happens later...

Like CSCO at $500B market Cap...
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.